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Background
Mastocytosis is a group of heterogeneous diseases char-
acterized by an abnormal expansion and accumulation of
mast cells (MCs) in different tissues. While systemic mas-
tocytosis (SM) is defined by the accumulation of MCs in
bone marrow (BM) and different tissues, cutaneous mas-
tocytosis (CM) is characterized as an accumulation of
MC in the skin with no other organ involvement. How
gender differences, tryptase levels and episodes of ana-
phylaxis affect cutaneous versus systemic mastocytosis is
not well understood.
Methods
We report a case series of 109 patients with SM and 59
with CM from the Mastocytosis Center at Brigham and
Women’s Hospital in Boston. The diagnosis of SM and
CM were done according to the International Classifica-
tion of Mastocytosis from WHO. We reviewed gender,
tryptase levels and episodes of anaphylaxis in both
populations.
Results
There was a female predominance which was more pro-
nounced in SM (68,8%) than in CM (52,7%). The mean
serum tryptase level was 11.5 ng/ml in CM, and 14.9% of
CM patients had serum tryptase levels above 20 ng/ml.
In SM patients the mean serum tryptase level was
97.2 ng/ml and 84% of the patients presented levels
above 20 ng/ml. The symptoms of CM included pruritus,
flushing, urticaria, and dermatographism and 10.8% of
the patients (number) had episodes of anaphylaxis. The
rate of anaphylaxis in SM patients was found to be 29.4%
similar to the previously reported.
Conclusions
A female predominance was seen in both cutaneous and
systemic mastocytosis in contrast to other studies indicat-
ing that there is no gender predominance. Elevations of
serum tryptase above 20 ng/ml and anaphylaxis were seen
in a small proportion of patients with cutaneous mastocy-
tosis, raising the question of the potential progression to
systemic mastocytosis and the need to closely monitor this
subset of patients.
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